10-Q – 2026-04-30 – cort-20260331.htm

(1)
In January 2026, we issued 70,869 shares of common stock as part of net-share settlement of cashless option exercises, of which 27,937 shares were surrendered to us in satisfaction of related exercise cost and tax obligations. In February 2026, we issued 324,037 shares of common stock as part of net-share settlement of cashless option exercises, of which 131,442 shares were surrendered to us. In March 2026, we issued 130,311 shares of common stock as part of net-share settlement of cashless option exercises, of which 45,207 shares were surrendered to us.

In January 2026, we issued 26,726 shares of common stock as part of restricted award vesting, of which 10,591 shares were surrendered to us in satisfaction of related tax obligations. In February 2026, we issued 78,739 shares of common stock as part of restricted award vesting, of which 31,554 shares were surrendered to us. In March 2026, we issued 44,468 shares of common stock as part of restricted award vesting, of which 17,007 shares were surrendered to us.

(2)
We paid $5.8 million to satisfy the tax withholding obligations associated with the net-share settlement of these cashless option exercises and restricted stock vesting.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
Not applicable.

ITEM 4.  MINE SAFETY DISCLOSURES
Not applicable.

ITEM 5.  OTHER INFORMATION
Insider Trading Arrangements
During the three months ended March 31, 2026, none of directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sales of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Security Exchange Act of 1934, as amended, or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K, other than as set forth in the table below.
41

Name Position Action Adoption Date Total Shares of Common Stock to be Sold Expiration Date (1)

James N. Wilson Director Adoption 3/12/2026 Up to 100,000
3/15/2027

(1)
Each trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales or (b) the date listed in the table.

42

ITEM 6.  EXHIBITS
Exhibit
Number   Description of Document
3.1   Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on May 24, 2023).

3.2   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on December 11, 2023).

31.1   Rule 13a-14(a)/15d-14(a) Certifications of Joseph K. Belanoff, M.D., Chief Executive Officer of the registrant.

31.2   Rule 13a-14(a)/15d-14(a) Certifications of Atabak Mokari, Chief Financial Officer of the registrant.

32.1   18 U.S.C. Section 1350 Certifications of Joseph K. Belanoff, M.D., Chief Executive Officer of the registrant.

32.2   18 U.S.C. Section 1350 Certifications of Atabak Mokari, Chief Financial Officer of the registrant.

101   The following materials from the registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Extensible Business Reporting Language (XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at March 31, 2026 and December 31, 2025, (ii) Unaudited Condensed Consolidated Statements of (Loss) Income for the three month periods ended March 31, 2026 and 2025, (iii) Unaudited Condensed Consolidated Statements of Comprehensive (Loss) Income for the three month periods ended March 31, 2026 and 2025, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the three month periods ended March 31, 2026 and 2025, (v) Unaudited Condensed Consolidated Statement of Stockholders’ Equity and (vi) Notes to Unaudited Condensed Consolidated Financial Statements.

104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

43

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  CORCEPT THERAPEUTICS INCORPORATED
   
Date: April 30, 2026 /s/ Joseph K. Belanoff
  Joseph K. Belanoff, M.D.
Chief Executive Officer
   
Date:
April 30, 2026 /s/ Atabak Mokari
  Atabak Mokari
  Chief Financial Officer

Date: April 30, 2026 /s/ Joseph D. Lyon
Joseph D. Lyon
Chief Accounting & Technology Officer

44